The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
Author:
- 27 January 2018
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 20 (1) , 5
Abstract
Sacubitril/valsartan (LCZ696) is a first-in-class, novel-acting, angiotensin receptor neprilysin inhibitor (ARNI) that provides inhibition of neprilysin and the angiotensin (AT1) receptor. A recent clinical trial PRARDIGM-HF demonstrated that this drug is superior to angiotensin-converting enzyme (ACE) inhibitors for improving the prognosis in the patients with heart failure, and this has resulted in the drug being included in clinical practice guidelines for the management of heart failure with reduced ejection fraction (EF). In addition, sacubitril/valsartan has been developed for the management of hypertension, because it has unique anti-aging properties. However, the clinical evidence of mechanism has not been well validated.Keywords
This publication has 56 references indexed in Scilit:
- Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervationHypertension Research, 2013
- Is very low dose hydrochlorothiazide combined with candesartan effective in uncontrolled hypertensive patients?Blood Pressure Monitoring, 2010
- Proposal of RAS-diuretic vs. RAS-calcium antagonist strategies in high-risk hypertension: insight from the 24-hour ambulatory blood pressure profile and central pressureJournal of the American Society of Hypertension, 2010
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyThe Lancet, 2010
- Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive PatientsHypertension, 2009
- Obstructive sleep apnea syndrome and hypertension: mechanism of the linkage and 24-h blood pressure controlHypertension Research, 2009
- Omapatrilat Reduces Pulse Pressure and Proximal Aortic Stiffness in Patients With Systolic HypertensionCirculation, 2002
- Omapatrilat Versus LisinoprilHypertension, 2001
- Isolated Systolic HypertensionHypertension, 1999
- Nocturnal Fall of Blood Pressure and Silent Cerebrovascular Damage in Elderly Hypertensive PatientsHypertension, 1996